<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013645</url>
  </required_header>
  <id_info>
    <org_study_id>FSUIRB0188</org_study_id>
    <nct_id>NCT05013645</nct_id>
  </id_info>
  <brief_title>Evaluation of Skin Hydration in Adults With Dry Skin Using a Moisturizer With an Added Sterilized Probiotic</brief_title>
  <acronym>DAMP</acronym>
  <official_title>Evaluation of Skin Hydration in Adults With Dry Skin Using a Moisturizer With an Added Sterilized Probiotic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dermatology Associates of Tallahassee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quorum Innovations</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Florida State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind placebo-controlled clinical trial to evaluate the effectiveness of a sterilized&#xD;
      probiotic on skin health and hydration in adults with dry skin.&#xD;
&#xD;
      The goal of the study is to determine if the addition of a skin-conditioning probiotic to a&#xD;
      standard gel product will moisturize the skin, support a healthy skin microbiome, and be&#xD;
      readily tolerated by adults with dry skin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneometer Measurements</measure>
    <time_frame>Study Days 1, 14, 28, 35</time_frame>
    <description>Measures change in skin surface hydration at study days 1, 14, 28 and 35</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tewameter Measurements</measure>
    <time_frame>Study Days 1, 14, 28, 35</time_frame>
    <description>Measures change in rate of skin surface water loss at study days 1, 14, 28, 35</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin microbiome analysis</measure>
    <time_frame>Study Days 1, 28</time_frame>
    <description>Changes in the composition (abundance and diversity) of skin lesional microbiome communities between Days 1 and 28 as demonstrated by genomic region amplification and analysis of sterile skin swab sample using standard protocols to compare associated organisms between the 2 time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Skindex16 Quality of Life over study days 1, 14, 28, 35</measure>
    <time_frame>Study Days 1, 14, 28, 35</time_frame>
    <description>Symptom-based scoring tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dry Skin Area and Severity Index (DASI) between study days 1 and 28</measure>
    <time_frame>Study Days 1, 28</time_frame>
    <description>Symptom-based scoring tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dryness Self Assessment (D-VAS) over study days 1, 14, 28 and 35</measure>
    <time_frame>Study Days 1, 14, 28, 35</time_frame>
    <description>Symptom-based scoring tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Itchiness Self Assessment (I-VAS) over study days 1, 14, 28 and 35</measure>
    <time_frame>Study Days 1, 14, 28, 35</time_frame>
    <description>Symptoms-based scoring tool</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dry Skin</condition>
  <arm_group>
    <arm_group_label>Sterilized probiotic (LfQi601)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sterilized probiotic topically administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gel control product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sterilized probiotic LfQi601</intervention_name>
    <description>Sterilized probiotic topically administered.</description>
    <arm_group_label>Sterilized probiotic (LfQi601)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Gel control product</description>
    <arm_group_label>Gel control product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of a signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability to attend&#xD;
             study visits for the duration of the study&#xD;
&#xD;
          3. English-speaking&#xD;
&#xD;
          4. 18-90 years of age&#xD;
&#xD;
          5. Score of a 2 or higher in one of the four areas assessed on the Dry Skin Area and&#xD;
             Severity Index (DASI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current self-reported pregnancy or active intent to conceive&#xD;
&#xD;
          2. Current lactation&#xD;
&#xD;
          3. Fever within 7 days of study enrollment&#xD;
&#xD;
          4. Self-reported use of systemic antibiotics (oral or injectable) in the past 6 weeks.&#xD;
&#xD;
          5. Any clinically significant medical or psychological disorder, condition, or disease&#xD;
             that in the opinion of the investigator exposes the subject to unacceptable risk by&#xD;
             participating in the study or interferes with the subject's ability to complete the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Berkes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida State University College of Medicine and Quorum Innovations</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Associates of Tallahassee</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Florida State University</investigator_affiliation>
    <investigator_full_name>Eva Berkes</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Probiotic</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

